After two decades of scientific exploration, the human microbiome has emerged as a critical determinant of health and disease. Fueled by multi-omics technologies and machine learning, the field has advanced from correlation-based observations to establishing causal relationships. This article presents recent and compelling examples of microbiome-based treatments that are ripe for clinical adoption and discusses challenges and opportunities facing the field based on expert interviews conducted by the GMFH team.
Phage therapy provides new hope for refractory and resistant bacterial infections
2 Dec 2024by Andreu Prados
As antibiotic-resistant infections continue to rise worldwide, phage therapy emerges as a promising alternative to antibiotics to tackle this public health threat.
Could the gut microbiota be a new potential target for multiple sclerosis treatment and prevention?
29 Aug 2016by Andreu Prados
A recent study, led by Dr. Ashutosh Mangalam, assistant professor of pathology at the University of Iowa Carver College of Medicine in Iowa City (USA), has found that gut microbiota changes may contribute to the disease course of multiple sclerosis.
